Can a generic drugmaker be held liable for failure-to-warn claims because its version of a popular drug gained U.S. Food and Drug Administration recognition as the industry standard?
That’s the theory plaintiffs lawyers in Atlanta have been pushing in a wrongful death suit against generic manufacturer Mylan and brand-name giant Pfizer. The plaintiffs argued that because Mylan’s maximum strength anti-seizure drug, phenytoin, had become the “reference listed drug” in a particular dosage class, they should be able to avoid dismissal under the U.S. Supreme Court’s decision last June in Pliva v. Mensing . In Mensing , the justices ruled 5-4 that state-law tort claims against generics are pre-empted because generics must follow federal labeling guidelines approved for brand-name manufacturers.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
